Recently, the Zuberitamab injection (Chinese trade name: 安瑞昔) of Zhejiang BioRay Biopharmaceutical Co., Ltd. is approved for marketing by China NMPA. This drug is indicated for the treatment of CD20 positive diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) for adult patients, and should be combined with standardized CHOP therapies (cyclophosphamide, doxorubicin, vincristine, prednisone).

　　Zuberitamab Injection is a human-mouse chimeric monoclonal antibody targeting the CD20 antigen on the surface of B cells. It can specifically bind to the CD20 antigen on the surface of B cells, thereby initiating the immune response of B cytolysis and exerting anti-tumor effects. The marketing of this drug provides more treatment options for patients.